ESR1 and breast carcinoma: These compounds demonstrated benefits (as monotherapy or in combination) in clinical studies, particularly in breast cancer (most beneficial estrogen-receptor positive; ER+), but also in melanoma, mantle cell lymphoma, non-small-cell lung cancer, and head and neck squamous cell carcinoma [29].